NOVARTIS AG-SPONSORED ADR (NVS)
US66987V1098 - ADR
Novartis Stock Just Below Innovative Drugmaker's All-Time High; Gets Key Rating Upgrade
Novartis stock is in a buy range after moving past a 103.55 entry in a cup with handle. The buy range extends to 5% above the initial entry.
Exploring NYSE:NVS's dividend characteristics.
Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) qualifies as a good dividend investing stock.
Here's Why Novartis (NVS) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
3 Crazy Good Stocks to Buy With $500 Right Now
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth.
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024
Seeking discounts in relevant places makes sense and there are few arenas more compelling than undervalued healthcare stocks.
The 3 Most Undervalued Healthcare Stocks to Buy in June 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to seeking discounts, investors may do well with undervalued heal...
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Goldman Sachs Says Buy European Pharma Stocks Touting Innovation
European drugmakers that are focused on building portfolios of new medicines have gotten a nod from analysts at Goldman Sachs Group Inc.
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
3 Magnificent Stocks That Are Passive Income Machines
These three companies have track records that should please investors.
3 Magnificent Stocks That Are Passive Income Machines
These three companies have track records that should please investors.
The 3 Best Mutual Funds to Buy in May 2024
Consider the best mutual funds to buy for high returns and low fees. They each have unique strategies meant to maximize returns on capital.
See Which Of The Latest 13F Filers Holds Novartis
3 Biotech Stocks to Sell in May Before They Crash & Burn
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio.
